Lisata Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Mazzo
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 110 Allen Road Basking Ridge NJ United States of America 07920
- IPO Date
- Mar 1, 1999
- CIK
- 0000320017
- Website
- lisata.com
- Similar Companies
- Business
- Lisata Therapeutics, Inc. Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage biopharmaceutical company that develops innovative therapies targeting advanced solid tumors and other serious diseases using its proprietary CendR Platform technology, which enables enhanced tumor-targeted and tissue-penetrating delivery of anti-cancer agents including chemotherapies, immunotherapies, and RNA-based therapeutics; the platform also selectively targets immunosuppressive cells within tumors to boost the patient's immune response. The company's lead product candidate, certepetide (formerly iRGD or CEND-1), is being evaluated in multiple ongoing clinical trials, such as the Phase 2 ASCEND study combining gemcitabine/nab-paclitaxel with certepetide or placebo for first-line metastatic pancreatic ductal adenocarcinoma in Australia and New Zealand, the Phase 2b trial of gemcitabine/nab-paclitaxel plus certepetide in China, the Phase 1 iLSTA trial adding certepetide to gemcitabine/nab-paclitaxel/durvalumab in Australia, the Phase 1 CENDIFOX trial with FOLFIRINOX plus panitumumab and certepetide for pancreatic, colon, and appendiceal cancers in the United States, the Phase 2 BOLSTER trial combining gemcitabine/cisplatin/durvalumab with certepetide or placebo for cholangiocarcinoma in the United States, and the Phase 2 trial of temozolomide with certepetide or placebo for glioblastoma multiforme in Estonia and Latvia. Founded in 1980 through predecessor entities and headquartered in Basking Ridge, New Jersey, Lisata conducts operations across the United States, Australia, New Zealand, China, and Europe, with subsidiaries including Lisata Therapeutics Australia Pty Ltd, Lisata Therapeutics Ireland Limited, Lisata Therapeutics Kabushiki Kaisha in Japan, and Lisata Therapeutics (UK) Limited. Recent developments include a strategic partnership expansion with GATC Health in June 2025 to leverage AI-driven Multiomics Advanced Technology for predicting combination therapies involving certepetide, enhancing drug discovery efficiency and derisking intellectual property; a global product license agreement with Catalent, Inc. initiated in October 2025 granting non-exclusive rights to incorporate certepetide into antibody-drug conjugates using Catalent's SMARTag technology platform, supported by positive preclinical data in November 2025 showing improved tumor penetration and efficacy; and FDA designations for certepetide including orphan drug status in pancreatic cancer since 2019 and Fast Track status since 2022.
Company News
Lisata adds biopharma finance veteran Jeffrey Farrow to board
Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Head to Head Analysis: GeoVax Labs (NASDAQ:GOVX) vs. Lisata Therapeutics (NASDAQ:LSTA)
Lisata Therapeutics wins new US patent for pancreatic cancer drug
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share